

MARKET REPORT



Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2017

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2017

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** pdb@bioportfolio.co.uk

Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2017

Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2017, provides an overview of the Multiple Myeloma (Kahler Disease) (Oncology) pipeline landscape.

Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. Multiple myeloma mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Multiple Myeloma (Kahler Disease) (Oncology)

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 13, 67, 68, 1, 3, 130, 23 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 7, 10, 1, 21 and 5 molecules, respectively.

Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler Disease) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Multiple Myeloma (Kahler Disease) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Multiple Myeloma (Kahler Disease) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Multiple Myeloma (Kahler Disease) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Myeloma (Kahler Disease) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Multiple Myeloma (Kahler Disease) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler Disease) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Additional Details

Publisher : Global Markets Direct

Reference : GMDHC9465IDB

Number of Pages : 1198

Report Format : PDF

Publisher Information :



Global Markets Direct
The home of leading edge research and analysis

BioPortfolio
Life Science Healthcare and Pharmaceutical
Market Research and Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

Table Of Contents for Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2017 [Report Updated: 30-06-2017]

- Table of ContentsTable of Contents 2Introduction 9Multiple Myeloma (Kahler Disease) - Overview 10Multiple Myeloma (Kahler Disease) - Therapeutics Development 11Multiple Myeloma (Kahler Disease) - Therapeutics Assessment 53Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development 78Multiple Myeloma (Kahler Disease) - Drug Profiles 154Multiple Myeloma (Kahler Disease) - Dormant Projects 1133Multiple Myeloma (Kahler Disease) - Discontinued Products 1147Multiple Myeloma (Kahler Disease) - Product Development Milestones 1150Appendix 1163

How to Buy...

Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2017 [Report Updated: 30-06-2017]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/100105>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at pdb@bioportfolio.co.uk or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$2500** | Single User Price
- \$5000** | Site License Price
- \$7500** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.